Vitamin B, E health claims
This article was originally published in The Tan Sheet
Executive Summary
Stay of litigation in Whitaker v. Shalala extended until Feb. 9 as FDA continues to review proposed vitamin E/heart disease claim and the parties negotiate language for a qualified B vitamin/vascular disease claim. Plaintiff dietary supplement marketers and developers continue to insist a CDC statement recognizing elevated plasma homocysteine as an independent risk factor for vascular disease should be included in any B vitamin claim. Previous litigation stay expired Jan. 12 (1"The Tan Sheet" Dec. 18, 2000, p. 7)